These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 17951903)

  • 21. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
    Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
    Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
    ; Scott IU; Edwards AR; Beck RW; Bressler NM; Chan CK; Elman MJ; Friedman SM; Greven CM; Maturi RK; Pieramici DJ; Shami M; Singerman LJ; Stockdale CR
    Ophthalmology; 2007 Oct; 114(10):1860-7. PubMed ID: 17698196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema.
    Mehta S; Blinder KJ; Shah GK; Kymes SM; Schlief SL; Grand MG
    Ophthalmic Surg Lasers Imaging; 2010; 41(3):323-9. PubMed ID: 20507016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
    Akinci A; Batman C; Ozkilic E; Altinsoy A
    Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.
    Arevalo JF; Garcia-Amaris RA; Roca JA; Sanchez JG; Wu L; Berrocal MH; Maia M;
    J Cataract Refract Surg; 2007 Dec; 33(12):2098-105. PubMed ID: 18053911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study.
    Velez-Montoya R; Fromow-Guerra J; Burgos O; Landers MB; Morales-Catón V; Quiroz-Mercado H
    Retina; 2009 Jan; 29(1):20-6. PubMed ID: 18784623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy.
    Gulkilik G; Taskapili M; Kocabora S; Muftuoglu G; Demirci G
    Int Ophthalmol; 2010 Dec; 30(6):697-702. PubMed ID: 20936526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
    Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
    Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
    Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
    Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
    Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
    Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.